Pituitary Volume in Medication-Naïve Adults With Obsessive Compulsive Disorder

The study subjects consisted of 50 medication-naïve patients with OCD and 40 matched health control subjects. The patients were recruited from the specialty OCD clinic at the National Institute of Mental Health And Neurosciences, Bangalore, India. The patients recruited never were exposed to psychotropic medications. Written informed consent was obtained from all subjects before assessment. The Institute Ethics Committee at the National Institute of Mental Health And Neurosciences reviewed and approved the research project from which the results of the present study are derived. The diagnosis of OCD was made according to the DSM-IV criteria.⁷ The Mini International Neuropsychiatric Interview was used to ascertain the diagnosis and to evaluate the presence of comorbid psychiatric conditions.⁸ The subjects were also evaluated with the Yale-Brown Obsessive Compulsive Scale (YBOCS) that includes a symptom checklist and severity rating scale.⁹ The Montgomery-Åsberg Depression Rating Scale (MADRS)¹⁰ was used to measure depressive symptoms. The clinical assessments were conducted by trained mental health professionals in the specialty OCD clinic, and the diagnosis was further confirmed by a consultant of the clinic (Y.C.J.R./G.V.S.). However, formal interrater reliability exercises were not conducted for the clinical data collection. Healthy control subjects who volunteered for participation in the study were recruited from consenting individuals from the community who were age, sex, and handedness matched. All subjects were right handed. Healthy control subjects were not evaluated using the severity rating scales (YBOCS and MADRS) because they screened negative for the psychiatric disorders on the Mini International Neuropsychiatric Interview. Subjects did not have a history of medical illness or substance dependence. There was no family history of psychiatric illness, including alcohol dependence syndrome, in their first-degree relatives.

The demographic and clinical details are summarized in Table 1. All the patients with OCD and healthy control subjects were matched for age and sex. The mean intracranial volume (in mL) was comparable between the groups (1453.81±158.02 versus1420.70±145.11, p=0.29). The mean age of onset of OCD was 20.90±7.83 years, and the median illness duration was 60 months. There was no significant difference in the pituitary volume between the two groups (687.80±126.60 versus 694.73±131.59, F=0.55, p=0.46). In addition, there was no difference in the volume on a separate analysis of male patients and female patients compared with the healthy control subjects of the respective sex. There were no significant correlations between YBOCS total scores and pituitary volume among OCD subjects (r=0.08, p=0.59). We found no significant correlations between the pituitary volume and duration of illness (r=0.05, p=0.73), age of onset (r=0.11, p=0.17), and MADRS score (mean=12.78±9.27; r=0.07, p=0.65). Among the subjects with OCD, 13 (26%) had comorbid lifetime depression and two (4%) had comorbid social anxiety disorder. We also compared the patients with OCD without any comorbid axis I conditions (N=35) with healthy control subjects and found no difference in the pituitary volumes (681.62±130.85 versus 694.72±131.59, F=0.90, p=0.35). A separate analysis comparing OCD patients without depression and healthy control subjects (p=0.42), and OCD patients with depression and healthy control subjects (p=0.18) did not yield significant results.

We did not find a significant difference in the pituitary volume between patients with OCD and healthy control subjects. We also did not observe any correlation between pituitary volume and the OCD severity. Some previous studies reported smaller pituitary volumes in pediatric⁴ and adult subjects^5,6 with OCD. Evidence suggesting HPA axis dysfunction has been reported among patients with OCD in the literature, with studies demonstrating elevated levels of cortisol,¹² corticotrophin-releasing hormone,¹³ and oxytocin,¹⁴ in addition to demonstrating smaller pituitary gland volume among patients with OCD compared with healthy control subjects.^4–6

Although previous studies have shown decreased pituitary volume in patients with OCD, the volume of this structure may be linked to a variety of factors. MacMaster et al.⁴ and Atmaca et al.⁶ demonstrated smaller volume of pituitary in pediatric and adult patients, respectively. However, replication of these findings is essential, considering some of the important confounders in most of these studies. First, the specificity of pituitary volume changes to diagnosis and comorbid conditions appear to be an important consideration. For instance, 26% of our subjects with OCD had comorbid lifetime depressive and anxiety disorders even though the current mean MADRS score was not high. However, the relatively smaller number of participants with OCD with comorbid depression in our study might not have been sufficiently powered to detect a difference in the region of interest analysis. In addition, comorbid personality disorders can also affect HPA axis structure and function,¹⁵ and this has not been assessed formally in this study or in previous studies on pituitary volume in OCD. Second, the mean age of onset of illness could also affect the pituitary because HPA dysregulation during peripubertal age may have greater consequences. The mean age at onset of OCD is late adolescence in our sample compared with peripubertal onset in some other studies on the topic. Third, the role of psychotropic medications on the pituitary needs to be considered. Antidepressants have a potentially significant effect on the functioning of HPA axis.¹⁶ Although Jung et al⁵ demonstrated a smaller pituitary volume in 12 medication-naïve individuals, this needs further examination in view of a small sample size. Our study reports on a large number of medication-naïve individuals with OCD, and this is in contrast to the previous studies. Finally, the factors apart from the main diagnoses such as life events play an important role on HPA regulation,¹ and hence it is important to take these factors into consideration while examining the brain changes.

Thus, although the HPA axis may play a role in the pathophysiology of OCD, one needs to carefully consider the above factors to ascertain the illness marker role of the HPA axis structures. In a cross-sectional study of this kind, it would be possible only to detect possible associations, and the stress-responsive nature of OCD might not be related to the development of the condition; rather, it could be a consequence of it. It would be interesting and informative to study the pituitary volume in a large sample medication-naïve patients with OCD without any comorbidity compared with healthy control subjects, because HPA abnormalities are more commonly seen with depression.¹⁷ Additionally, longitudinal studies would provide evidence for the pathoplastic effect of illness course and duration on pituitary structure.

J.C.N. is supported by the DST-INSPIRE faculty award project, Government of India. D.J. is supported by an INSPIRE faculty grant to J.C.N. S.V.K. is supported by the Wellcome Trust DBT grant to G.V.S.